199 related articles for article (PubMed ID: 3871589)
21. A perspective on the present contribution of beta-lactamases to bacterial resistance with particular reference to induction of beta-lactamase and its clinical significance.
Neu HC; Chin NX
Chemioterapia; 1985 Feb; 4(1):63-70. PubMed ID: 3872725
[TBL] [Abstract][Full Text] [Related]
22. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Brogden RN; Heel RC
Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
[TBL] [Abstract][Full Text] [Related]
23. Effects of beta-lactamase-mediated antimicrobial resistance: the role of beta-lactamase inhibitors.
Maddux MS
Pharmacotherapy; 1991; 11(2 ( Pt 2)):40S-50S. PubMed ID: 2041831
[TBL] [Abstract][Full Text] [Related]
24. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus.
Chambers HF; Sachdeva M; Kennedy S
J Infect Dis; 1990 Sep; 162(3):705-10. PubMed ID: 2387996
[TBL] [Abstract][Full Text] [Related]
25. The in-vitro activity and beta-lactamase stability of carumonam.
Neu HC; Chin NX; Labthavikul P
J Antimicrob Chemother; 1986 Jul; 18(1):35-44. PubMed ID: 3531143
[TBL] [Abstract][Full Text] [Related]
26. In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria.
Mitsuhashi S
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():53-64. PubMed ID: 6607914
[TBL] [Abstract][Full Text] [Related]
27. [Beta-lactam antibiotics].
Inoue M; Okamoto R
Nihon Rinsho; 1990 Oct; 48(10):2178-83. PubMed ID: 2280461
[No Abstract] [Full Text] [Related]
28. MEN 10700, a new penem antibiotic: in-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall.
Fontana R; Altamura M; Arcamone F; Mazzariol A; Morandotti G; Sperning R; Cornaglia G
J Antimicrob Chemother; 1998 May; 41(5):513-25. PubMed ID: 9630405
[TBL] [Abstract][Full Text] [Related]
29. Binding of a non-beta-lactam antibiotic to penicillin-binding proteins.
Nozaki Y; Katayama N; Ono H; Tsubotani S; Harada S; Okazaki H; Nakao Y
Nature; 1987 Jan 8-14; 325(7000):179-80. PubMed ID: 3543695
[TBL] [Abstract][Full Text] [Related]
30. Sch 29482: activity against susceptible and beta-lactam resistant variants of Enterobacteriaceae.
Chabbert YA; Jaffé A
J Antimicrob Chemother; 1982 Feb; 9 Suppl C():203-12. PubMed ID: 6977531
[No Abstract] [Full Text] [Related]
31. Aztreonam.
Cunha BA
Urology; 1993 Mar; 41(3):249-58. PubMed ID: 8442309
[TBL] [Abstract][Full Text] [Related]
32. In-vitro activity of tigemonam, an oral monobactam, against gram-negative rods, including variants in beta-lactamase-production.
Brown J; Yang YJ; Livermore DM
J Antimicrob Chemother; 1989 Feb; 23(2):201-7. PubMed ID: 2785102
[TBL] [Abstract][Full Text] [Related]
33. Lipopolysaccharide alterations responsible for combined quinolone and beta-lactam resistance in Pseudomonas aeruginosa.
Leying HJ; Büscher KH; Cullmann W; Then RL
Chemotherapy; 1992; 38(2):82-91. PubMed ID: 1591950
[TBL] [Abstract][Full Text] [Related]
34. The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam.
Jones RN; Barry AL; Thornsberry C; Fuchs PC; Packer RR
Am J Clin Pathol; 1986 Nov; 86(5):608-18. PubMed ID: 3096130
[TBL] [Abstract][Full Text] [Related]
35. Antibacterial properties of Ro 40-6890, a broad-spectrum cephalosporin, and its novel orally absorbable ester, Ro 41-3399.
Angehrn P; Hohl P; Hubschwerlen C; Page M; Then R
Antimicrob Agents Chemother; 1992 Dec; 36(12):2825-34. PubMed ID: 1482153
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial combinations in the therapy of infections due to gram-negative bacilli.
Allan JD; Moellering RC
Am J Med; 1985 Feb; 78(2A):65-76. PubMed ID: 3918445
[TBL] [Abstract][Full Text] [Related]
37. Genetic and biochemical basis of resistance of Enterobacteriaceae to beta-lactam antibiotics.
Wiedemann B
J Antimicrob Chemother; 1986 Oct; 18 Suppl B():31-8. PubMed ID: 3491818
[TBL] [Abstract][Full Text] [Related]
38. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.
Sumita Y; Fukasawa M
J Antimicrob Chemother; 1995 Jul; 36(1):53-64. PubMed ID: 8537284
[TBL] [Abstract][Full Text] [Related]
39. Review of the in vitro spectrum of activity of imipenem.
Jones RN
Am J Med; 1985 Jun; 78(6A):22-32. PubMed ID: 3890537
[TBL] [Abstract][Full Text] [Related]
40. Current state of infectious diseases--potential areas of directed therapy with aztreonam.
Neu HC
Am J Med; 1985 Feb; 78(2A):77-80. PubMed ID: 4038580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
